Kangcen Pharmaceuticals: KC1086 completes Phase I clinical trial with the first subject enrolled

Kangchen Pharmaceutical announced that its independently developed KC1086 tablet has recently successfully completed the enrollment of the first subject in the Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of KC1086 in the treatment of advanced recurrent or metastatic solid tumors. KC1086 is a small molecule inhibitor of lysine acetyltransferase 6 with a completely new structure, which is intended for the treatment of late-stage recurrent or metastatic solid tumors.